Benzinga | Jul 13, 2020 08:33AM EDT

Bellerophon Therapeutics Announces First Patient Treated In Phase 3 Clinical Study Of INOpulse Inhaled Nitric Oxide Therapy For COVID-19

Initiation of the COViNOX Study Follows the Conclusion of the FDA Emergency Access Program Through Which 180 Patients with COVID-19 Were Treated in the United States

WARREN, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the first patient has initiated treatment in the Company's Phase 3 clinical study of INOpulse(r) inhaled nitric oxide (iNO) therapy for the treatment of COVID-19 (COViNOX) at Banner University Medical Center, within the University of Arizona College of Medicine -- Phoenix, under the direction of Dr. Thomas Ardiles, clinical assistant professor and Dr. Marilyn Glassberg, professor of medicine and chief of the Pulmonary, Critical Care and Sleep Division. The Company's Investigational New Drug application for the Phase 3 study with INOpulse was accepted by the U.S. Food and Drug Administration in May 2020.